RAF1 and central nervous system cancer: To determine whether this was true in our glioma models, we quantified RAS-GTP levels in response to short-term MEKi versus control using a RAF1-RAS binding domain (RAF1-RBD) based immunoprecipitation to extract the fraction of RAS that is GTP-bound and able to bind RAF1.